Prostate cancer

Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029

Retrieved on: 
Thursday, March 21, 2024
Diagnosis, University, Qiagen, Breast cancer, PerkinElmer, Lung cancer, Medical device, Research, Government, Burn, Drug discovery, Health, Pressure, Growth, Prevalence, Organization, Learning, Figure, Prostate cancer, The BMJ, Tufts University, Incidence, Thermo Fisher Scientific, COVID-19, Danaher Corporation, Conditional sentence, American Cancer Society, RNA, DNA, Female, Robotics, Cancer, Software, Wyss Institute, Laboratory, Woman, Regenerative medicine, Harvard University, Drug development, Xenobot, Medical journal, Pharmaceutical industry

DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.
  • The molecular robotics market is expected to witness a CAGR of 18% over the forecast period.
  • Active participation of universities in drug research and molecular robotics is also supporting the growth of the studied market.
  • Most of the players focus on bringing technologically advanced products into the market to acquire the maximum market share.

Renowned Los Angeles Urologist Dr. Justin Houman Appointed Assistant Professor at Cedars-Sinai Medical Center

Retrieved on: 
Wednesday, March 20, 2024
Diagnosis, Peyronie's disease, Health, Infertility, Prostate cancer, Assistant, Knowledge, Research, Fertility, Patient, Suite, Male, Cedars-Sinai Medical Center, Publication, Urinary tract infection, Erectile dysfunction, LOS, Kidney, Assistant professor

LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist, as Assistant Professor in the esteemed Department of Urology. With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.

Key Points: 
  • Dr. Justin Houman, M.D., brings expertise in clinical care, research, and medical education to Cedars-Sinai's Department of Urology.
  • LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist , as Assistant Professor in the esteemed Department of Urology.
  • With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.
  • In his role as Assistant Professor, Dr. Houman will impart invaluable knowledge and mentorship to medical students, residents, and fellows in urology.

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2023 CHALLENGE AWARDS TOTALING MORE THAN $21 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Thursday, March 14, 2024
University of Illinois Urbana-Champaign, PCF, University of Sydney, Prostate cancer, Genetic testing, Immunotherapy, Prostate Cancer Foundation, Lund University, Oncogene, Patient, PET, Biomarker, Research, Aircraft pilot, University, Doctor of Philosophy, Biology, MBA, MPH, Johns Hopkins University, Institute of Cancer Research, CBP, University of Pretoria, PSMA, Medical imaging

LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.
  • PCF Challenge Awards fund international, multi-institutional, cross-disciplinary teams of investigators conducting highly innovative research with the greatest potential for accelerating new and improved treatments for advanced prostate cancer.
  • Following a rigorous peer review process that assessed each project's scientific merit and potential patient impact, 20 highly coveted PCF Challenge Awards totaling $21.3 million were granted to teams at some of the world's leading cancer research institutions.
  • (Evaluating the impact of treatment with darolutamide on age-related outcomes in vulnerable, older patients with metastatic hormone-sensitive prostate cancer.)

2024 JUSTICE RUTH BADER GINSBURG LEADERSHIP AWARD HONORS ELON MUSK, SYLVESTER STALLONE, MARTHA STEWART, MICHAEL MILKEN, AND RUPERT MURDOCH

Retrieved on: 
Wednesday, March 13, 2024
Ruth Bader Ginsburg, Champ, Democracy, Congress, Veteran, Prostate Cancer Foundation, Portrait, HM, RBG, Prostate cancer, Rocky, Woman, Bangladesh Technical Education Board, Supreme court, Justice, Parity, Thomas Jefferson Building, Sole proprietorship, Multimedia, Musk, Parent

RBG Leadership Award expands to honor Elon Musk, Sylvester Stallone, Martha Stewart, Michael Milken & Rupert Murdock

Key Points: 
  • RBG Leadership Award expands to honor Elon Musk, Sylvester Stallone, Martha Stewart, Michael Milken & Rupert Murdock
    Established in 2020, the RBG Award has previously recognized women of distinction, including HM Queen Elizabeth II and Barbra Streisand.
  • "Justice Ginsburg fought not only for women but for everyone," said Julie Opperman, Chair of the Dwight D. Opperman Foundation.
  • "Justice Ginsburg became an icon by bravely pursuing her own path and prevailing against the odds," said Brendan V. Sullivan, Jr., chair of the RBG Award.
  • Murdoch said: "I am deeply honored to receive the Justice Ruth Bader Ginsburg Leadership Award from the Dwight D. Opperman Foundation.

Enhancing Prostate Cancer Screening: AI, Imaging and Clinical Innovations, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Algorithm, MRI, Prostate cancer, Radiology, Medical imaging, Magnetic resonance imaging, Partnership, Prostate-specific antigen, PET, Bachelor of Science, Artificial intelligence, AI, Doctor of Philosophy, MBBS, University College London, Workforce, PSA

TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests. The featured speakers will also discuss the critical role artificial intelligence (AI) will play in combination with clinical and imaging tests to deliver sustainable, patient-centric screening pathways.

Key Points: 
  • In this free webinar, learn about the evolution of prostate cancer screening and the shift to magnetic resonance imaging (MRI)-based diagnostic tools for more accurate screening.
  • The featured speakers will share insights into the development of AI-based algorithms in prostate cancer, including best practices and pitfalls.
  • The speakers will also discuss ongoing clinical studies shaping the future of prostate cancer detection and treatment.
  • TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests.

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Retrieved on: 
Tuesday, March 12, 2024
MSD, PARG, Apoptosis, Prostate cancer, Endometrial cancer, Colorectal cancer, RECIST, Patient, MSI, Merck & Co., Pembrolizumab, Medicine, MSS, Breast cancer, HRD, Therapy, ADP, PD-1, Pharmaceutical industry

"We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.

Key Points: 
  • "We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.
  • "We are very pleased to collaborate with Merck on this trial evaluating IDE161 in combination with KEYTRUDA in patients with MSI-high and MSS endometrial cancer.
  • Under the clinical trial collaboration and supply agreement, Merck will provide KEYTRUDA to IDEAYA, which will be the sponsor of the Phase 1 clinical combination trial.
  • The mechanistic rationale and preclinical data to support the IDE161 and PD-1 clinical combination will be provided as part of a future R&D update.

Silent cancers: here’s what you need to know when there are no obvious symptoms

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Research, Health, Princess, Metabolism, Colorectal cancer, Prostate cancer, Metabolomics, Disease, Risk, Patient, Biomarker, Weight loss, Perception, Neoplasm, DNA, Breast, Malignancy, Prostate, Mammography, Cancer, Medicine, Woman, Fatigue, HPV, Google Images, CRC, Breast cancer, Large intestine, Blood, Medical imaging

Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.

Key Points: 
  • Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.
  • While even silent cancers can sometimes be aggressive and advance rapidly, they can also remain dormant for years or even decades.
  • Some prostate, breast and thyroid cancers, for example, often evolve slowly without obvious symptoms or spreading beyond the original area.

The importance of early diagnosis

  • Whatever the cancer, it’s always important to get an early diagnosis though – and for silent cancers, this is obviously a challenge.
  • But such symptoms can be misinterpreted or easily dismissed, which contributes to delayed diagnosis and treatment.
  • Fortunately, in many countries including the UK, we have screening tests for diseases like breast or colon cancer, to increase early diagnoses.
  • Early diagnosis is a key factor for successful cancer treatment.

Biomarker discovery

  • From molecular profiling to liquid biopsy techniques (blood tests to diagnose cancer), innovative approaches are reshaping the landscape of cancer diagnosis, offering new avenues for personalised and precision medicine.
  • For example, I worked with a team using blood tests to identify cancers in more than 1,000 women recalled after screening for mammography.
  • Although there’s increasing awareness and use of this approach in Europe, it isn’t standard in the UK.


Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.